MARKET WIREYahoo Finance UK • 12h ago
Cerus Corporation (CERS) stock price, news, quote and historyYahoo Finance UK report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
Why CERS Stock dropped -6.56% Today — RQD Quant Desk Flash
$2.28 -6.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.25
Cerus Corporation (CERS) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $491.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CERS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Cerus Corporation (NASDAQ: CERS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.28 (-6.56% 1D, market cap $491.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CERS ranks #843 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CERS compare to BWAY and SSII in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), CERS carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.5%. By comparison, BWAY (BrainsWay Ltd.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $478.7M) and SSII (SS Innovations International Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $477.2M). Among the 5-stock peer group, CERS leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CERS?
▼
Per CERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001020214), Cerus Corporation generated $233.8M in revenue (+16.1% YoY), -$15.6M in net income, and $1.1M in free cash flow against $221.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.25 (-1.37%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-12.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CERS)Realized 20D OHLCV Swing Band: ±8%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY CERS SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (27% of score)
20D Institutional Volume Accumulation (±8% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 6/9
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$2.26-1.8% Next Q
22
Q2 (-2Q)Grade E$2.22+6.8% Next Q
25
Q3 (-1Q)Grade E$2.37-3.8% Next Q
27
CurrentGrade E$2.28-9.6% Hist 90D α
30
Trajectory: E (22) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CERS Turnaround Squeeze
While CERS currently carries a cautious 30/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.46) and Max Pain ($2.39) forces dealer call-delta covering toward $3.64.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CERS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CERS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CERS Stock dropped -6.56% Today — RQD Quant Desk Flash
Cerus Corporation (CERS) dropped -6.56% to $2.28, trading at 43% of its 52-week range ($1.38 – $3.47). Stretched risk/reward at current multiples (-16% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 43% of its 52-week range ($1.38 – $3.47) with RSI-14 at 53.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8% around $2.28 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $1.1M annual free cash flow.
Live CERS Headlines & Catalysts
MARKET WIREMarketBeat • 15h ago
Cerus Corporation (CERS) - What Are Analysts Saying About This Stock?MarketBeat report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.marketscreener.com • 18h ago
Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026www.marketscreener.com report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 21h ago
A workshop will share one hospital's experience using treated platelets and a clotting productStock Titan report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Cerus And 2 Other Compelling Penny Stocks To WatchSimply Wall St report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Cerus stock has November 5, 2026 earnings date and USD 63.25 million estimatead-hoc-news.de report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHMarketBeat • 1d ago
Cerus (NASDAQ:CERS) Stock Rating Cut to "Hold" at Wall Street ZenMarketBeat report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Cerus sets November 2 results date for Cerus stockad-hoc-news.de report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 4h ago
Cerus Q3 Earnings Call HighlightsCerus (NASDAQ:CERS) reported third-quarter product revenue growth of 10% year over year and reaffirmed its 2026 revenue outlook, while also announcing positive top-line results from its Phase III RedeS study of pathogen-
CATALYSTChartMill • 5h ago
Cerus Corp (NASDAQ:CERS) Posts In-Line Q3 Revenue and Positive RedeS DataCerus (NASDAQ:CERS) Q3 2026 revenue rose 6% to $64M, EPS beat estimates, and positive Phase 3 RedeS data lifted pipeline; shares slipped after hours.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CERS)
- ✓Walkthrough of CERS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CERS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.18%📐 WEDGE COMPRESSION COIL
2026-11-02O $2.42H $2.44L $2.28C $2.28VOL 1.35M
RES: $2.46SUP: $2.13SMA50: $2.46SMA200: $2.45
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CERS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +16.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CERS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CERS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CERS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CERS)
Health Care Rank #843 of 1016
⚔️ BWAY vs CERS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CERS vs. BWAY, SSII, DCTH, SENS)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Cerus Corporation (CERS) ranks #843 by composite RQD confidence (30/100, grade E) and #456 by equity capitalization ($491.7M). Within this direct 5-issuer industry benchmark cohort, CERS leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with CERS at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CERS
ACTIVE
Cerus Corporation | E | 30/100 | — | — | -15.5% | -6.56% | $491.7M | Benchmark Subject |
| BWAY BrainsWay Ltd. | D | 47/100 | — | — | — | -4.78% | $478.7M | /bway-vs-cers → |
| SSII SS Innovations International Inc. | E | 30/100 | — | 46.0% | -18.5% | -1.26% | $477.2M | /ssii-vs-cers → |
| DCTH Delcath Systems Inc. | C | 62/100 | — | 86.2% | 0.8% | -4.10% | $508.0M | /dcth-vs-cers → |
| SENS Senseonics Holdings Inc. | D- | 41/100 | — | 44.7% | -35.0% | -2.46% | $515.5M | /sens-vs-cers → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001020214In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cerus Corporation (CERS) reported GAAP revenue of $233.8M (+16.1% vs. FY2024 revenue of $201.3M , and +25.2% cumulative change since FY2023) , GAAP net income of -$15.6M, operating cash flow of $4.8M, and free cash flow of $1.1M (-87.0% YoY). On the balance sheet, CERS closed FY2025 with $221.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $233.8M | -$15.6M | $4.8M | $1.1M | $221.9M | — |
| FY2024 (FY) | 2024-12-31 | $201.3M | -$20.9M | $11.4M | $8.5M | $200.9M | — |
| FY2023 (FY) | 2023-12-31 | $186.8M | -$37.5M | -$43.2M | -$43.2M | — | — |
3. CERS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Cerus Corporation (NASDAQ: CERS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.28 (-6.56% 1D, market cap $491.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CERS ranks #843 in composite RQD confidence.
How does CERS compare to BWAY and SSII in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), CERS carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.5%. By comparison, BWAY (BrainsWay Ltd.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $478.7M) and SSII (SS Innovations International Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $477.2M). Among the 5-stock peer group, CERS leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CERS?
Per CERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001020214), Cerus Corporation generated $233.8M in revenue (+16.1% YoY), -$15.6M in net income, and $1.1M in free cash flow against $221.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CERS trading relative to its 50-day, 200-day, and 52-week technical levels?
CERS last traded at $2.28 (-6.56% on volume of 1,503,459 shares), positioning the stock -7.32% below its 50-day simple moving average ($2.46) and -6.94% below its 200-day simple moving average ($2.45). Across its 52-week range of $1.38 to $3.47, CERS sits at the 43.1% percentile with a 14-day RSI of 53.9 (NEUTRAL RANGE) and an implied next-earnings move of ±8.0% ($2.10 to $2.46).
CERS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CERS stock moving today?
Why CERS Stock dropped -6.56% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-16% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 30/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
CERS — Cerus Corporation: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:35:54Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CERS scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4 / 20 (ROIC -15.5%; FCF yield 0.23%), Whale 13F Flow at 8 / 20 (institutional accumulation and options positioning), Insider Conviction at 5 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8 / 20 (Altman Z 0.2; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillar is Fundamental Cash Engine, which means the company's return on invested capital and free-cash-flow yield are the primary drag on the score. For a prospective investor evaluating the stock today, the implication is that the rating framework flags elevated forensic and cash-generation risk, with the low Altman Z-Score as the most prominent balance-sheet concern. Upside drivers within this framework are limited to the moderate institutional and balance-sheet readings; valuation tradeoffs cannot be fully assessed because P/E and EV/EBITDA are not available in source data.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $233.8M | $-8.7M | $-15.6M | N/A | $1.1M | $20.0M | N/A |
| FY 2024 | $201.3M | $-14.2M | $-20.9M | N/A | $8.5M | $20.3M | N/A |
| FY 2023 | $186.8M | $-30.1M | $-37.5M | N/A | $-43.2M | N/A | N/A |
Per the SEC financials, revenue rose from $186.8M in FY 2023 to $233.8M in FY 2025 while net losses narrowed from $-37.5M to $-15.6M. The per-market-data operating margin is -3.7%, net margin is -6.7%, and gross margin is 0%, with ROIC at -15.5%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5; the low Altman Z-Score signals elevated distress risk, while the Piotroski reading is moderate. Reported FY 2025 cash of $20.0M and FY 2025 FCF of $1.1M provide limited liquidity cushion against continued operating losses.
Recent Catalysts & News Wire Analysis
Per the news wire, six items reference CERS, all tagged with a YELLOW light and MARKET WIRE impact label. Headlines include a Yahoo Finance UK market report, a MarketBeat analyst-opinion piece, a MarketScreener notice that Cerus will release Q3 2026 financial results on November 2, 2026, a Stock Titan item describing a workshop on treated platelets and a clotting product, a Simply Wall St penny-stock roundup, and an ad-hoc-news.de item citing a November 5, 2026 earnings date and a USD 63.25 million estimate. The Q3 2026 results release is the most time-sensitive catalyst in the source set. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals.
Open Questions
- What are the reported EPS, P/E, and EV/EBITDA figures, given that these fields are absent from the source data?
- What is the company's reported debt balance for FY 2024 and FY 2025, given that debt is recorded as N/A for each period?
- What drove the FY 2025 operating loss of $-8.7M and the cash balance trend between FY 2024 and FY 2025?
- What were the actual results disclosed in the Q3 2026 release scheduled for November 2, 2026, relative to the USD 63.25 million estimate?
- Who are the company's principal products, customers, and competitors, since the business description is not available in source data?
CERS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Cerus Corporation (CERS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 12h ago
Cerus Corporation (CERS) stock price, news, quote and history Yahoo Finance UK report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 15h ago
Cerus Corporation (CERS) - What Are Analysts Saying About This Stock? MarketBeat report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 18h ago
Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026 www.marketscreener.com report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 21h ago
A workshop will share one hospital's experience using treated platelets and a clotting product Stock Titan report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Cerus And 2 Other Compelling Penny Stocks To Watch Simply Wall St report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Cerus stock has November 5, 2026 earnings date and USD 63.25 million estimate ad-hoc-news.de report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH MarketBeat • 1d ago
Cerus (NASDAQ:CERS) Stock Rating Cut to "Hold" at Wall Street Zen MarketBeat report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Cerus sets November 2 results date for Cerus stock ad-hoc-news.de report covering Cerus Corporation (CERS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CERS Bull vs. Bear Conversation Board — What's Your Call at $2.28?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CERS 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $2.15 (-11.9%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is CERS (E • RQD 30/100) a Buy at $2.44?
Welcome to the CERS (Cerus Corporation) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $2.03 (-16.8%)
Spot @ $2.44 Pump the brakes on CERS — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on CERS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cerus Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $2.93 (+20.1%)
Spot @ $2.44 CERS cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on CERS, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $2.44 (52-wk range $1.38 - $3.47), any beat on forward guidance forces shorts and underweight funds to chase.